The Positive
+ Surge in revenue. 1Q21 revenue jumped 47% YoY to a record S$43mn. Core dental business was up 41% to S$39.2mn. The remaining revenue came from PCR tests and equipment that more than doubled to S$4.5mn. Revenue was supported by a 7.6% increase in dental clinics to 122. Admissions were also higher. With borders closed and more time available, households could opt for more regular and elective dental procedures. Due to strict MOH requirements, revenue from PCR test kits is no longer separately disclosed.
+ Interim DPS. Net debt declined from S$75mn in FY19 to S$20mn in FY20. FCF was S$19mn. Another S$47mn was collected from the disposal of Aidite in 1H20. Q & M announced a special DPS of 2.5 cents to return S$19mn to shareholders from the proceeds of its sale of Aidite.
+ Higher Covid-19 PCR test earnings. PCR revenue was not disclosed. We used minority interest of S$0.6mn during the quarter as PATMI contributions from PCR. With PCR tests rising in Singapore, we double our daily test assumption for FY21e to 1,200. Q & M’s ability to ramp capacity is limited by a short supply of lab technicians in the country.
The Negative
– Short-term impact on revenue. While the country has entered a Phase 2 heightened alert lockdown from 16 May, dental clinics are allowed to stay open. However, we do expect cancellations. Patients will be wary of going for dental procedures despite all the safeguards in place. During the circuit breaker last April, dental clinics were not allowed to undertake any aerosol-generating procedures. This meant 90% of the procedures were prohibited except for extractions and temporary fillings.
Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.
He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.